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ABSTRACT
Anticancer drugs still are dosed based on the body-
surface area (BSA) of the individual patient, although the
BSA is not the main predictor of the clearance for the
majority of drugs. The relevance of BSA-based dosing has
not been evaluated for topotecan yet. A retrospective phar-
macological analysis was performed of kinetic data from
four clinical Phase I studies in which topotecan was admin-
istered p.o. as a single agent combined with data from a
combination study of topotecan and cisplatin. A strong cor-
relation (r 5 0.91) was found between the area under the
plasma concentration time curve of the lactone and carbox-
ylate forms of topotecan by plotting 326 data sets obtained
from 112 patients receiving oral topotecan at dose levels
ranging from 0.15–2.70 mg/m2. The intrapatient variability,
studied in 47 patients sampled for 3 or more days, for the
apparent lactone clearance, ranged from 7.4–69% (mean,
24 6 13%; median, 20%). The interpatient variabilities in
the lactone clearance, calculated with the data of all studied
patients, expressed in liter/h/m2 and in liter/h were 38% and
42%, respectively. In view of the relatively high inter- and
intrapatient variabilities in topotecan clearance, in contrast
to a variability of only 12% in the BSA of the studied
patients, no advantage of BSA-based dosing was found over
fixed dose regimens.
INTRODUCTION
Most anticancer drugs are dosed based on the BSA2 of the
individual patient, with the aim of reducing interpatient varia-
bility of drug exposure. However, this strategy failed for most
drugs (1), except for docetaxel (Taxotere), where BSA has been
shown to be a main predictor of the clearance in a pharmaco-
kinetic model (2). The relevance of this concept of BSA-based
dosing has not been evaluated for topotecan (Hycamtin), one of
the most promising agents that entered the clinical practice in
recent years. Topotecan has antitumor activity against various
human malignancies, and relationships have clinically been
found between systemic exposure of topotecan and hematolog-
ical toxicity (reviewed in Refs. 3–5) and with antitumor activity
in preclinical models (6). The bioavailability of oral topotecan in
adult cancer patients ranged from 30–44% with interpatient
variabilities of 26–31% (7–9). However, because pharmacoki-
netic analysis in most patients (10–12) has been carried out for
only 2 days, a reliable estimate of the intrapatient variability of
p.o. administered topotecan has not yet been established. The
recommended dose for single-agent oral topotecan is 2.3 mg/
m2/day for 5 days every 3 weeks. As an alternative, a fixed dose
of 4 mg/day for 5 days every 3 weeks was proposed (10).
However, thus far, studies on oral topotecan have been per-
formed by dosing patients based on their BSA instead of using
fixed dose regimens. Because most patients will take their oral
medication in an outpatient setting, it is important to keep
dosing regimens as simple as possible, and, because of this, it
would be most practical to use fixed dosing regimens (13). The
aim of the present analysis of kinetic data from several Phase I
studies was to investigate whether dosing of oral topotecan in
the treatment of adult cancer patients based on BSA of individ-
ual patients has any advantage over fixed dose regimens.
PATIENTS AND METHODS
Patient Selection. The patient selection criteria were
fully described elsewhere for the oral Phase I studies in which
topotecan was administered as a single agent (3) and for the
study in which oral topotecan was combined with i.v. cisplatin
(14). In short, patients with a confirmed diagnosis of a malig-
nant solid tumor resistant to standard chemotherapy regimens
were eligible for these studies. Age should be between 18 and 75
years, and performance status, defined by the Eastern Cooper-
ative Oncology Group, had to be #2. No previous anticancer
therapy for at least for 4 weeks was allowed. Adequate hema-
topoietic and renal functions were required, and patients with
mildly impaired liver functions (i.e., total serum bilirubin
#1.25 3 upper normal limit; and aspartate aminotransferase
and alanine aminotransferase #2 3 upper normal limits and, in
case of liver metastases, #3 3 upper normal limits) were
allowed to participate in the described studies. A specific ex-
clusion criterion was the existence of any gastrointestinal cir-
cumstance, which could alter the absorption of topotecan. All
patients signed informed consent.
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Treatment Schedules in the Single-Agent Phase I
Studies. Oral administration, using the i.v. formulation, of
single-agent topotecan was studied in four Phase I studies (3).
The first study involved a twice daily dosing of topotecan at
dose levels of 0.15–0.60 mg/m2 for 21 days, repeated every 28
days (3, 11). In the second study, topotecan was administered
twice daily for 10 days, every 21 days, at dose levels of 0.50–
0.80 mg/m2 (3, 12). In the third study, the administration of
topotecan was reduced to once a day for 10 days at dose levels
ranging from 1.00–1.60 mg/m2 (3, 12). The final Phase I study
of single-agent oral topotecan involved a once daily adminis-
tration for 5 days, also repeated every 21 days, and included
dose levels ranging from 1.20–2.70 mg/m2 (3, 10). In the daily
for 5 days schedule also patients were included who were
treated with a fixed dose of 4 mg/day.
Treatment Schedule in the Combination Phase I Study.
The latter mentioned regimen of oral topotecan, this time at dose
levels ranging from 0.75–2.30 mg/m2/day for 5 days, using the
drug formulated in gelatin capsules, was also studied combined
with a fixed dose of 75 mg/m2 i.v. cisplatin (14). In the present
study, we also included pharmacokinetic data of patients treated
with oral topotecan daily for 5 days, at dose levels of 1.50 and
1.75 mg/m2, preceded by a 3-h cisplatin infusion at 50 mg/m2 on
day 1 of each course in an ongoing study, using the same
eligibility criteria as reported previously (14).
Pharmacokinetic Sample Collection and Analysis.
Blood samples were collected, up to 12 h after dosing (10–12,
14), in 4.5-ml glass tubes containing lithium heparin as antico-
agulant and were centrifuged within 10 min to separate the
plasma. Subsequently, the plasma was deproteinized by 4-fold
dilution in ice-cold (220°C) methanol, resulting in a stabilized
lactone:carboxylate ratio (15), and stored at 280°C upon anal-
ysis. Simultaneous determination of the lactone and carboxylate
form of topotecan was performed by a reversed-phase high-
performance liquid chromatographic method, as described (15),
with minor modifications for the analysis of drug levels in the
combination Phase I study (14).
On the basis of the best fitted curves, two and three
compartmental analysis models after zero-order input were used
for the calculation of the AUC0-infinity of the lactone as well as
the carboxylate form of topotecan, as described (14). The ap-
parent CL/F of topotecan lactone was calculated by dividing the
dose per m2 by the observed lactone AUC, expressed in liter/
h/m2. The absolute CL/F, expressed in liter/h, was calculated by
dividing the absolute dose by the AUC of topotecan lactone.
Statistical Analysis. Linear regression analysis was per-
formed, using the NCSS package (version 5.X, 1992; J. L.
Hintze, East Kaysville, UT), to test potential relationships be-
tween evaluated parameters. One-way ANOVA was performed
to evaluate statistically significant differences (P , 0.05) be-
tween groups, using the same program.
RESULTS
In the four Phase I studies on single-agent oral topotecan,
56 patients were evaluable for pharmacokinetic analysis for a
total of 114 kinetic days (Table 1). The majority of evaluable
days were obtained in the Phase I trial studying the combination
of oral topotecan and i.v. cisplatin, in which 56 patients were
sampled for a total of 228 days (Table 2).
By plotting 326 data sets (95% of total) of kinetic days for
which both the lactone and the carboxylate AUC could be
assessed, a strong linear relationship was found between the
AUCs of the pharmacological active lactone form of topotecan
and its inactive ring-opened carboxylate form (AUCcarboxylate 5
1.62 1 1.57*AUClactone, r 5 0.91; Fig. 1). For further estima-
tion of inter- and intrapatient variabilities and their implication
Table 1 Evaluable pharmacokinetic days in the four single-agent Phase I studies of orally administered topotecan
Dose (mg/m2) Twice daily Once daily No. of patients
Total number of evaluable kinetic courses
Day 1 Day 4 Day 8 Day 21 Total
0.15 21 days 2 2 1 3
0.30 21 days 3 3 3 6
0.40 21 days 2 3 2 2 7
0.50 21 days 4 4 4 8
0.60 21 days 3 3 3 6
0.50 10 days 1 1 1 2
0.60 10 days 4 3 4 7
0.70 10 days 4 4 4 8
0.80 10 days 1 1 1
1.00 10 days 3 3 3 6
1.40 10 days 3 3 3 6
1.60 10 days 4 4 4 8
1.20 5 days 3 3 3 6
1.80 5 days 3 3 3 6
2.30 5 days 6 6 6 12
2.70 5 days 4 4 4 8
1.25a 10 days 1 1 1 2
4.00a 5 days 6 6 6 12
Totalb 56 57 22 33 2 114
a Fixed dose.
b One patient in the twice daily 0.40 mg/m2 was also sampled during course 2, and one patient in the once daily 1.40 mg/m2 was also sampled
during a course with a fixed dose of 1.25 mg.
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for BSA dosage regimens, pharmacokinetic parameters of the
lactone form were used in this analysis.
Inter- and Intrapatient Variability. Because the major-
ity of the patients in the single-agent oral Phase I studies were
sampled for pharmacokinetic analysis for only 2 days during
one cycle, the intrapatient pharmacokinetic parameter variabil-
ities for topotecan lactone were studied using the data obtained
in the topotecan/cisplatin combination Phase I study, in which
pharmacokinetic sampling was performed during several cycles.
As already reported, there was no pharmacokinetic interaction
between oral topotecan and i.v. cisplatin (14). In view of this, all
kinetic days (with and without cisplatin) were used for the
present analysis. The intrapatient variability in AUC and CL/F
of topotecan lactone was calculated as the SD divided by the
average, using only data from the 47 patients who had at least
three evaluable kinetic courses of the AUC of topotecan lactone.
The average intrapatient variability in the lactone AUC across
all dose levels was 24 6 13% (median, 20%; range, 7.6–61%).
The average intrapatient variability in the CL/F, expressed in
liter/h/m2 and in liter/h, was 24 6 13% (median, 20%; range,
7.4–69%).
The interpatient variability in CL/F, expressed in liter/h/m2
as well as in liter/h, was calculated using the data of all of the
patients, by using the averaged apparent CL/F of all kinetic days
of each patient as single value. The average apparent CL/F was
103 6 39.0 liters/h/m2 (CV 5 38%, n 5 107; Fig. 2A), with no
significant difference (P 5 0.074) in the CL/F over the 19
studied dose levels. The average apparent CL/F, studied over 27
different individual dosages, was 194 6 80.4 liters/h (CV 5
42%, n 5 107; Fig. 2B) or 195 6 81.1 liters/h (CV 5 42%, n 5
114; Fig. 2B), by inclusion of the patients treated with a fixed
dose.
In addition, no alteration in topotecan lactone kinetics was
found (P 5 0.30) after multiple (up to six) courses (Fig. 3),
using the data of patients treated in the combination Phase I
study, in which patients were samples for multiple courses.
BSA as Determinant for Dose Calculations. As shown
in Figs. 2 and 3, the apparent CL/F was constant over the studied
dose ranges and courses. In Fig. 4, the BSA is plotted versus
absolute apparent CL/F in liters/h (mean 6 SD), calculated with
the actual dose given to each individual patient. A poor positive
relationship was found between BSA and the average apparent
CL/F (CL/F 5 52.4175.1*BSA, r 5 0.29), with large variabil-
ities in the apparent CL/F across all studied BSA values in the
47 patients with three or more pharmacologically evaluable
courses.
DISCUSSION
Dosing of most cytotoxic agents is commonly based on the
BSA of patients, intending to reduce interpatient pharmacoki-
netic variabilities of a compound. This, in turn, is based on an
assumed relationship between the clearance of a compound and
the BSA of the individual patient (1, 13). However, calculation
of the exact clearance of topotecan is not feasible because the
compound has a reversible conversion from the lactone to the
carboxylate form. Moreover, accurate dosing of oral topotecan
based on BSA is also not feasible, because for oral use the drug
is now only available as gelatin capsules containing 1.0 and 0.25
mg, respectively, resulting in the necessity of rounding of the
absolute dose to the nearest quartile mg. Because excretion by
the kidneys is a major route of elimination of topotecan (re-
viewed in Ref. 4) and alterations in the pharmacokinetic param-
eters for topotecan have only been described in patients with a
renal dysfunction (i.e., creatinine clearance ,60 ml/min; Ref.
16), in the set of studies we performed an altered topotecan
clearance was not expected. The apparent CL/F of oral topote-
Table 2 Evaluable pharmacokinetic days in the Phase I study in which oral topotecan was combined with i.v. cisplatin
Dose (mg/m2) No. of patients
Total number of evaluable kinetic days
C1d1 C1d2 C1d5 C2d1 C2d5 C3d1 C3d5 C6d1 C6d2 C6d5 Total
0.75 6 6 6 6 6 6 6 36
1.00 6 6 6 6 6 6 6 36
1.25 11 10 4 11 5 5 4 4 2 2 1 48
1.50 9 9 5 8 3 3 1 1 1 31
1.75 10 10 6 9 3 3 31
2.00 8 6 3 7 4 4 24
2.30 7 7 7 4 4 22
Totala 56 54 18 54 31 31 16 16 3 3 2 228
a One patient received 2.30 mg/m2 (course 1) and 2.00 mg/m2 (course 2).
Fig. 1 Relationship between the AUCs of the lactone and carboxylate
form of topotecan in 326 evaluable data sets.
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can, in patients with a normal renal function, is highly depend-
ent on the absorption of the lactone form from the gastrointes-
tinal tract.
The oral bioavailability of topotecan in adult cancer pa-
tients for drinking of the i.v. solution ranged from 30 6 7.7% (7)
to 44% (9) and was found to be 42 6 13% for the drug
formulated in gelatin capsules (8). In these clinical studies,
interpatient variabilities in the oral availability in adults ranged
from 26–31% (7, 8), which is not dissimilar to the interpatient
variability of 38% and 42% for the apparent CL/F expressed in
liter/h/m2 and in liter/h, respectively, in our studies. Because the
interpatient variability was calculated with the average apparent
CL/F of topotecan lactone, using the data of patients who were
studied up to six times, this variability might even be underes-
timated.
Only limited information was available on the intrapatient
variability of p.o. administered topotecan in adult cancer
patients. Gerrits et al. (3) reported intrapatient variabilities in
AUC of topotecan lactone of 25 6 31% (n 5 22) and 35 6 25%
(n 5 10) in clinical Phase I studies in which topotecan was
administered either once daily for 5 days or 10 days, respec-
tively, and of 97 6 70% (n 5 10) and 60 6 51% (n 5 13) in
the twice daily for 10 days and 21 days schedules, respectively.
Because samples were collected only for pharmacokinetic anal-
ysis on 2 treatment days during one cycle, an accurate estima-
tion of the intrapatient variability was not possible. In this
present analysis, we assessed the intrapatient variability using
Fig. 2 Plot of dose/m2 (A) and absolute dose (B) and the averaged
apparent CL/F (patients with a fixed dose are indicated by triangles).
Fig. 3 Apparent CL/F during multiple courses and days.
Fig. 4 BSA versus absolute apparent CL/F expressed in liter/h
(mean 6 SD).
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data of 47 patients, who were sampled on 3–6 days each,
resulting in an average intrapatient variability of the lactone
AUC of 24 6 13% (median 20%), with a range of 7.6- 61%.
The broad range in the intrapatient variability in lactone AUC
after oral administration of topotecan is probably related to the fact
the carboxylate form is poorly absorbed from the small intestine,
whereas the lipophilic pharmacological active lactone form of
topotecan is able to pass the membranes of the small intestine (4).
Because the pH in the small intestine ranges from pH 5–7 and the
rate of interconversion between the lactone and carboxylate form of
topotecan is pH dependent, the amount of topotecan that is avail-
able for absorption is related to a fluctuation in the pH.
We did not find saturation of the absorption, tissue distri-
bution, or elimination of p.o. administered topotecan over the
studied dose range of 0.15–2.70 mg/m2 apparent from a lack in
significant difference in the observed CL/F over the dose range
studied. Also, administration of multiple (up to six) courses of
p.o. administered topotecan did not alter the apparent topotecan
lactone CL/F.
The interpatient variability in the topotecan CL/F of 38% and
42%, expressed in liter/h/m2 and liter/h respectively, is much larger
than the 12% interpatient variability in BSA of our patients (aver-
age BSA, 1.9 6 0.22 m2, n 5 107). In view of the intrapatient
variability of 24 6 13% in the apparent lactone CL/F, with indi-
vidual variabilities up to 69%, the interpatient variability in the
bioavailability of 26–31%, and the poor relationship between the
BSA and the average apparent CL/F, we feel that there is no
scientific rationale for BSA-based dosing of p.o. administered
topotecan in adult patients. This confirms our previous observation
of similar pharmacokinetics after oral administration of either 2.3
mg/m2 topotecan or a fixed dose of 4 mg (10), which was already
suggesting that fixed-dose regimens could be applied.
In conclusion, in view of the relatively high intra- and
interpatient variabilities in the AUC and CL/F of topotecan
lactone and the relatively small range in observed BSA, oral
topotecan can be added to the list of agents where BSA-adjusted
dosing does not seem definitely better (1). We recommend a
fixed dose regimen for future use in clinical trials, which is more
convenient for the oncologist and the pharmacist, is more cost-
effective, and, last but not least, is less cumbersome for the
patients. Further randomized clinical studies in a large popula-
tion are needed to fully explore the advantages of fixed dose
regimens of p.o. administered topotecan, in which simulta-
neously the need for potential dosage adjustments at extreme
BSA values have to be investigated.
A careful study of interpatient variability of topotecan
AUC in patients of the same BSA and renal and hepatic func-
tion, to look at the effects of factors as age, gender, protein
binding, and inherited or acquired metabolic function, in addi-
tion to expression of the MDR-1 P-glycoprotein and BCRP
drug-transporting proteins (17) in intestinal tissues as an expla-
nation for this variability, is currently being conducted.
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